Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings results on Monday. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02, Briefing.com reports. The firm had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The company’s revenue was up 41.5% compared to the same quarter last year.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at $41.10 on Tuesday. Supernus Pharmaceuticals has a 12 month low of $17.25 and a 12 month high of $50.04. The stock has a market capitalization of $2,131.90, a P/E ratio of 36.89, a PEG ratio of 1.84 and a beta of 1.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.74 and a current ratio of 1.94.

In other news, VP Padmanabh P. Bhatt sold 3,709 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total transaction of $167,758.07. Following the sale, the vice president now owns 17,500 shares in the company, valued at approximately $791,525. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total value of $4,426,050.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 153,709 shares of company stock worth $7,223,108. Company insiders own 6.70% of the company’s stock.

Several equities research analysts have commented on the company. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 target price on the stock. in a research note on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies restated a “hold” rating and issued a $45.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Cowen and Company restated a “positive” rating and issued a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 3rd. BidaskClub cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Janney Montgomery Scott restated a “hold” rating and issued a $47.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $49.78.

WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/07/supernus-pharmaceuticals-inc-supn-announces-quarterly-earnings-results.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.